362 related articles for article (PubMed ID: 22392042)
1. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
Masciari S; Dillon DA; Rath M; Robson M; Weitzel JN; Balmana J; Gruber SB; Ford JM; Euhus D; Lebensohn A; Telli M; Pochebit SM; Lypas G; Garber JE
Breast Cancer Res Treat; 2012 Jun; 133(3):1125-30. PubMed ID: 22392042
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic features of breast cancer in Li-Fraumeni syndrome.
Kuba MG; Lester SC; Bowman T; Stokes SM; Taneja KL; Garber JE; Dillon DA
Mod Pathol; 2021 Mar; 34(3):542-548. PubMed ID: 32636452
[TBL] [Abstract][Full Text] [Related]
3. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
[TBL] [Abstract][Full Text] [Related]
5. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations.
Wilson JR; Bateman AC; Hanson H; An Q; Evans G; Rahman N; Jones JL; Eccles DM
J Med Genet; 2010 Nov; 47(11):771-4. PubMed ID: 20805372
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
7. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
Le AN; Harton J; Desai H; Powers J; Zelley K; Bradbury AR; Nathanson KL; Shah PD; Doucette A; Freedman GM; Gabriel P; Domchek SM; MacFarland SP; Maxwell KN
Breast Cancer Res Treat; 2020 May; 181(1):181-188. PubMed ID: 32246378
[TBL] [Abstract][Full Text] [Related]
8. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
[TBL] [Abstract][Full Text] [Related]
9. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
10. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.
Henry E; Villalobos V; Million L; Jensen KC; West R; Ganjoo K; Lebensohn A; Ford JM; Telli ML
J Natl Compr Canc Netw; 2012 Aug; 10(8):939-42. PubMed ID: 22878818
[TBL] [Abstract][Full Text] [Related]
11. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
14. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
15. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
16. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
18. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
19. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
20. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
